PolyPid (PYPD) has released an update.
PolyPid Ltd. has completed patient enrollment for the interim analysis of its SHIELD II Phase 3 trial, testing D-PLEX100 for preventing surgical site infections, with results expected soon. The company reported a net loss for Q3 2024, driven by increased R&D expenses, but maintains a strong cash position to fund operations into 2025, with potential to extend into 2026. Investors keeping a close eye on the upcoming trial outcomes may find PolyPid’s strategic financial management noteworthy.
For further insights into PYPD stock, check out TipRanks’ Stock Analysis page.
